243 related articles for article (PubMed ID: 28388861)
1. Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic.
Wallace JL; Vaughan D; Dicay M; MacNaughton WK; de Nucci G
Antioxid Redox Signal; 2018 Jun; 28(16):1533-1540. PubMed ID: 28388861
[TBL] [Abstract][Full Text] [Related]
2. The effect of hydrogen sulfide-releasing naproxen (ATB-346) versus naproxen on formation of stress-induced gastric lesions, the regulation of systemic inflammation, hypoxia and alterations in gastric microcirculation.
Magierowski M; Magierowska K; Surmiak M; Hubalewska-Mazgaj M; Kwiecien S; Wallace JL; Brzozowski T
J Physiol Pharmacol; 2017 Oct; 68(5):749-756. PubMed ID: 29375050
[TBL] [Abstract][Full Text] [Related]
3. ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo.
De Cicco P; Panza E; Ercolano G; Armogida C; Sessa G; Pirozzi G; Cirino G; Wallace JL; Ianaro A
Pharmacol Res; 2016 Dec; 114():67-73. PubMed ID: 27777130
[TBL] [Abstract][Full Text] [Related]
4. The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine.
Mostafa DK; El Azhary NM; Nasra RA
Can J Physiol Pharmacol; 2016 Jul; 94(7):699-708. PubMed ID: 27088818
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen sulfide releasing naproxen offers better anti-inflammatory and chondroprotective effect relative to naproxen in a rat model of zymosan induced arthritis.
Dief AE; Mostafa DK; Sharara GM; Zeitoun TH
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1537-46. PubMed ID: 25967731
[TBL] [Abstract][Full Text] [Related]
6. Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease.
Li Z; Polhemus DJ; Lefer DJ
Circ Res; 2018 Aug; 123(5):590-600. PubMed ID: 30355137
[TBL] [Abstract][Full Text] [Related]
7. H
Magli E; Perissutti E; Santagada V; Caliendo G; Corvino A; Esposito G; Esposito G; Fiorino F; Migliaccio M; Scognamiglio A; Severino B; Sparaco R; Frecentese F
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944543
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics.
Wallace JL; Blackler RW; Chan MV; Da Silva GJ; Elsheikh W; Flannigan KL; Gamaniek I; Manko A; Wang L; Motta JP; Buret AG
Antioxid Redox Signal; 2015 Feb; 22(5):398-410. PubMed ID: 24635322
[TBL] [Abstract][Full Text] [Related]
9. Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
Donnarumma E; Ali MJ; Rushing AM; Scarborough AL; Bradley JM; Organ CL; Islam KN; Polhemus DJ; Evangelista S; Cirino G; Jenkins JS; Patel RA; Lefer DJ; Goodchild TT
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381758
[TBL] [Abstract][Full Text] [Related]
10. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.
Campolo M; Esposito E; Ahmad A; Di Paola R; Wallace JL; Cuzzocrea S
FASEB J; 2013 Nov; 27(11):4489-99. PubMed ID: 23901068
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter.
Wallace JL; Wang R
Nat Rev Drug Discov; 2015 May; 14(5):329-45. PubMed ID: 25849904
[TBL] [Abstract][Full Text] [Related]
12. Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases.
Peng W; Guo W; Zheng Y
Curr Top Med Chem; 2021; 21(24):2230-2242. PubMed ID: 34488613
[TBL] [Abstract][Full Text] [Related]
13. Hydrogen Sulfide Switch Phenomenon Regulating Autophagy in Cardiovascular Diseases.
Luo W; Gui DD; Yan BJ; Ren Z; Peng LJ; Wei DH; Liu LS; Zhang DW; Jiang ZS
Cardiovasc Drugs Ther; 2020 Feb; 34(1):113-121. PubMed ID: 32090295
[TBL] [Abstract][Full Text] [Related]
14. Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis.
Paul-Clark M; Elsheikh W; Kirkby N; Chan M; Devchand P; Agbor TA; Flannigan KL; Cheadle C; Freydin M; Ianaro A; Mitchell JA; Wallace JL
PLoS One; 2016; 11(2):e0147289. PubMed ID: 26910063
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition.
Bucci M; Vellecco V; Cantalupo A; Brancaleone V; Zhou Z; Evangelista S; Calderone V; Papapetropoulos A; Cirino G
Cardiovasc Res; 2014 Apr; 102(1):138-47. PubMed ID: 24501330
[TBL] [Abstract][Full Text] [Related]
16. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer.
Elsheikh W; Blackler RW; Flannigan KL; Wallace JL
Nitric Oxide; 2014 Sep; 41():131-7. PubMed ID: 24747869
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory and cytoprotective properties of hydrogen sulfide.
Gemici B; Wallace JL
Methods Enzymol; 2015; 555():169-93. PubMed ID: 25747480
[TBL] [Abstract][Full Text] [Related]
18. SG1002 and Catenated Divalent Organic Sulfur Compounds as Promising Hydrogen Sulfide Prodrugs.
Gojon G; Morales GA
Antioxid Redox Signal; 2020 Nov; 33(14):1010-1045. PubMed ID: 32370538
[No Abstract] [Full Text] [Related]
19. The Drug Developments of Hydrogen Sulfide on Cardiovascular Disease.
Wen YD; Wang H; Zhu YZ
Oxid Med Cell Longev; 2018; 2018():4010395. PubMed ID: 30151069
[TBL] [Abstract][Full Text] [Related]
20. A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide.
Verma R; Akhtar Y; Singh S
Recent Pat Drug Deliv Formul; 2017; 11(2):114-123. PubMed ID: 28901845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
